Introduction
============

Several inherited retinal diseases present at birth, manifesting as nystagmus and decreased vision in infants \[[@r1]\]. These retinal conditions, such as Leber congenital amaurosis (LCA) and congenital stationary night blindness (CSNB), represent genetically and clinically heterogeneous groups of retinal disorders. Accurate diagnosis of an infant with decreased vision is often difficult, as presentations within the groups can overlap. Furthermore, LCA, achromatopsia, and CSNB can all present initially with a normal fundus appearance. Thus, precise diagnosis relies on electroretinography (ERG) and genetic diagnostic testing. In general, infants with severely attenuated or nonrecordable photopic and scotopic responses on ERG are diagnosed as having LCA, whereas those with absent cone-specific ERG responses and normal rod function are thought to have achromatopsia \[[@r1]\]. A ratio of the scotopic b-wave to a-wave amplitude of less than one (i.e., an electronegative waveform) indicates a possible diagnosis of CSNB \[[@r2]\]. However, performing ERGs in infants can be challenging, and ERG responses continue to mature throughout the first year of life, making it difficult to interpret responses measured in infancy and to attain a definitive diagnosis early in disease \[[@r3]\].

CSNB can be further classified as type 1 (CSNB1) or type 2 (CSNB2), depending on symptoms and abnormalities on the ERG \[[@r4]\]. CSNB1, or complete CSNB, is characterized by predominant night blindness, mildly decreased visual acuity, moderate to high myopia, and nystagmus that tends to lessen with time \[[@r4]\]. On ERG testing, the scotopic b-wave is unrecordable, but the photopic system is less abnormal, with typical broadening of the a-wave, due to absent photopic ON responses visible on photopic cone-specific ERG responses. The phenotype of CSNB2, or incomplete CSNB, is less distinct, and patients can present with impaired night vision, decreased visual acuity (VA), a variable degree of refractive error, nystagmus, light sensitivity, and the characteristic electronegative waveform on ERG \[[@r2],[@r4]\]. ERG also shows a reduced but recordable scotopic b-wave, reduced photopic b-wave, and reduced 30-Hz flicker, due to abnormalities at the level of the scotopic and photopic ON and the photopic OFF responses \[[@r4],[@r5]\]. CSNB2 can be difficult to diagnose due to its relatively low incidence and lack of specific symptoms. Furthermore, studies have shown that at least one of the major phenotypic features (night blindness, decreased visual acuity, myopia, and nystagmus) may be absent in up to three-quarters of cases \[[@r6]-[@r8]\].

The lack of specific symptoms and ocular findings in CSNB2 makes genetic testing a necessary component of diagnosis \[[@r8]\]. CSNB2 is most often caused by mutations in the *CACNA1F* gene (MIM\#300110) \[[@r6],[@r9],[@r10]\], which encodes the α1F subunit of Ca~v~1.4, a retina-specific voltage-gated L-type calcium-channel located in the membrane of photoreceptor and bipolar cell ribbon synapses \[[@r11],[@r12]\]. Ca~V~1.4 (α1F) knockout mouse models and mice with null mutations exhibit abnormally formed synaptic ribbons and cone photoreceptors, and outgrowth of rod bipolar and horizontal cell processes into the outer retina \[[@r13]-[@r15]\]. Furthermore, knock-in mice with the equivalent amino acid change of a known mutation in human *CACNA1F*, p.(Ile756Thr), also show immature ribbon synapses and diminished cone and rod photoreceptor terminals \[[@r16],[@r17]\]. These findings support the long-postulated reduced signal transfer to ON and OFF bipolar cells as the reason for the decreased b-wave amplitudes and night blindness, reduced best-corrected visual acuity (BCVA), as well as photophobia in CSNB2 \[[@r10],[@r11]\].

Interestingly, mutations in *CACNA1F* have also been linked to cone-rod dystrophy 3 (CORDX3), Åland island eye disease (AIED), and X-linked retinitis pigmentosa (XLRP), supporting the idea that one gene can be involved in multiple clinical entities \[[@r18]-[@r20]\]. Retinal dystrophies often present as a spectrum of clinical findings that do not always concur with a defined set of diagnostic characteristics, especially in infancy. Here, we describe two cases that further illustrate this theme. These patients were seen at the clinic with an initial presentation suggestive of LCA, including severely reduced photopic and scotopic functions on ERG and nystagmus, but upon genetic testing, they were found to have novel mutations in *CACNA1F*. This report demonstrates the significant overlap in phenotypes between LCA and CSNB2 and emphasizes that genotype often cannot be predicted by phenotype. We further propose that the classification of diseases by genotype (*CACNA1F*-associated retinal dystrophy) provides a more precise diagnosis for patients rather than the traditional phenotypic names (CSNB, LCA, etc.).

Methods
=======

The study protocol was approved by the Institutional Review Boards of Massachusetts Eye and Ear Infirmary (MEEI), Boston Children's Hospital (BCH), and the Children's Hospital of Philadelphia (CHOP). Patients were recruited and clinically evaluated at three centers (Electroretinography Service at MEEI and BCH and the Ophthalmic Genetics & Visual Electrophysiology Clinic at CHOP), and the parents of the patients provided informed written consent for the study. This research adhered to the tenets of the Declaration of Helsinki and was conducted in accordance with the Health Insurance Portability and Accountability Act.

Clinical evaluation
-------------------

The patients underwent a full ophthalmic examination which included best-corrected preferential looking and Kay picture tests, followed by Snellen visual acuity depending on age, visual field testing on the Goldmann perimeter with the V-4e white test light, the Lang Stereotest, the Ishihara 38 plate color test, the Farnsworth Dichotomous-15 color vision test, dark adaptation testing performed with the Goldmann-Weekers dark adaptometer, and full-field ERG testing. ERG responses were obtained following protocols as described elsewhere \[[@r21]-[@r23]\]. To summarize, a calibrated photodiode (IL1700; International Light, Newburyport, MA) with a scotopic or photopic filter was used at BCH to measure stimulus strength. For the dark-adapted eye, responses to full field, blue stimuli were recorded over a 5 log unit range (from -2 to 3 log scot td s) at increments of 0.3 log unit steps. Cone and cone-driven responses were recorded to a range of red flashes (0.3 -- 35 cd·s/m^2^) presented on a steady, white rod-saturating background (25.5 cd/m^2^). Photopic function was also tested with a 30-Hz flickering stimulus of 2.25 cd·s/m^2^ \[[@r21]\]. At MEEI, full-field ERGs were elicited in response to single flashes of 0.5 Hz dim blue light, 0.5 Hz white light, and 30 Hz white light at durations of 10 µs \[[@r22]\]. At CHOP, full-field ERGs were obtained according to ISCEV standards as outlined previously \[[@r23]\]. 0.01 cd·s/m^2^ was used for rod stimulation, 3.0 cd·s/m^2^ for all other standard responses, and 30 cd/m^2^ for light adaptation and background luminance. After parents of the patients provided informed consent, blood samples were collected from the patients and available family members for DNA extraction. Blood samples were collected from the patients and available family members. Leukocyte DNA was purified using standard procedures.

Genetic analysis
----------------

Before the current study, both patients had undergone limited genetic diagnostic testing at several testing laboratories. The testing included testing for identified mutations in known LCA disease genes (the John and Marcia Carver Nonprofit Genetic Testing Laboratory, Iowa City, IA) and direct sequencing of the LCA and/or RP genes in-house and through the ARUP Laboratories (Associated Regional and University Pathologists, Inc., Salt Lake City, UT).

The patients then underwent more thorough genetic testing for the studies reported here. Patient 1 was genetically diagnosed with whole-exome sequencing of the patient and available family members. The whole-exome libraries (SureSelect Human All Exon V4, Agilent Technologies, - Santa Clara, CA) were sequenced on a HiSeq platform (Illumina, Inc., San Diego, CA) as previously reported \[[@r24]\]. Patient 2 was genetically screened with targeted exon sequencing with the Genetic Eye Disease (GEDi) test, as previously described \[[@r25]\]. Briefly, the custom SureSelect targeted enrichment GEDi capture kit (Agilent Technologies, Inc, Santa Clara, CA) was designed to capture and enrich coding exons and select deep intronic regions associated with 257 genes, including known IRD genes, early-onset glaucoma and optic atrophy genes, and candidate IRD disease genes. The targeted enrichment GEDi capture set included all currently known monogenic inherited retinal degeneration genes \[[@r25]\]. GEDi targeted enrichment sample sequencing was performed on a MiSeq NGS platform (Illumina, Inc.).

NGS sequencing data were analyzed using custom and publicly available tools. The Burrows-Wheeler Aligner (BWA) was used to align the sequence reads to the human reference genome (GRCh37) and SAMtools to remove potential duplicates and identify initial single nucleotide polymorphisms (SNPs) and insertions and deletions \[[@r26],[@r27]\]. Custom and publicly available variant filtering programs were applied to remove likely false positive calls \[[@r27],[@r28]\]. The resulting variant calls were annotated using a custom human base-pair codon resource and public resources \[[UCSC Genome Browser](ttp://genome.ucsc.edu/), ENSEMBL, [1000 Genomes Project](http://www.1000genomes.org/), Exome Variant Server ([EVS](http://evs.gs.washington.edu/EVS/)), [SIFT](http://sift.jcvi.org/), and [PolyPhen-2](http://genetics.bwh.harvard.edu/pph2/)\] \[[@r29],[@r30]\]. Variants were filtered by frequency (\<0.15%) based on the EVS database and the Single Nucleotide Polymorphism Database ([dbSNP),](http://www.ncbi.nlm.nih.gov/SNP/)as before \[[@r31]\]. Non-synonymous variants, nonsense mutations, potential splice-site changes, and rare synonymous variants were considered. Rare synonymous changes were evaluated in terms of the possibility of affecting splicing.

Mutations in *CACNA1F* were confirmed through Sanger sequencing and cosegregation analysis in available family members. Regions of interest were PCR amplified (*Taq* DNA Polymerase, Life Technologies, Carlsbad, CA), purified (ExoSap-IT, Affymetrix, Santa Clara, CA), and sequenced (BigDye Terminator v3.1, ABI 3730xl, Life Technologies, Grand Island, NY). Regions of interest were PCR amplified for 35 cycles using the following conditions: denaturation at 95°C, annealing at 60°C, and extension at 72°C. Variant annotations were performed according to the transcript ENST00000376265.

Results
=======

Case 1
------

Patient 1 (OGI 117_301) presented at age 3.5 months with nystagmus, which had been noted by his parents since 1 month after birth. He showed fixation on faces and seemed to have normal visual attention. The fundus exam was normal. The ERGs were notable for decreased scotopic and photopic responses with amplitudes of rod-specific, maximal combined rod-cone, and cone-specific responses at 10% of normal ([Figure 1A](#f1){ref-type="fig"}). No obvious electronegative aspect of the maximal combined rod-cone response was noted at that time. A preliminary clinical diagnosis of LCA was made. However, genetic testing for mutations in previously identified LCA genes was negative.

![Exam findings for Patient 1. **A**: Full-field flash electroretinography according to International Society for Clinical Electrophysiology of Vision (ISCEV) standards is shown at ages 3.5 months (black traces) and 7.5 months (gray traces). At 3.5 months, the electroretinogram (ERG) traces showed notably decreased amplitudes in the rod and cone responses, with the amplitudes in the rod-specific, maximal combined rod-cone, and cone-specific responses at 10% of normal. No obvious electronegative aspect was evident at that time. At 7.5 months, the ERG traces showed significantly reduced amplitudes in the rod and cone responses and an electronegative waveform on maximal responses. Control ERGs performed at the same institution for a healthy 8-month-old are included for comparison (red traces). DA = dark adapted; LA = light adapted. **B**: Right and left fundus photographs showing essentially normal fundi at age 4 years. **C**: Family pedigree of Patient 1.](mv-v23-695-f1){#f1}

At 7.5 months, the maximal combined ERG response began to show an electronegative waveform ([Figure 1A](#f1){ref-type="fig"}), which was confirmed more clearly at age 4 years. The fundus exam was normal at that time ([Figure 1B](#f1){ref-type="fig"}). His nystagmus had resolved by age 10 months, and he had no refractive error. His parents also noted that his fixation on objects and faces improved, and his BCVA was 20/60 oculus dexter (OD) and 20/70 oculus sinister (OS) at age 4 (Appendix 1). There was no history of vision loss or consanguinity in the family ([Figure 1C](#f1){ref-type="fig"}). Using whole-exome sequencing, a new nonsense mutation in *CACNA1F* was discovered at c.966 G\>A, resulting in truncation of the protein at codon 332 \[p.(Trp332\*)\].

Case 2
------

The parents of Patient 2 (D226--1) brought him to the clinic after noticing "flickering of eyes" since age 3 weeks. On his first ophthalmologic exam at 5 months, the patient was interactive and visually responsive. He had vertical nystagmus, visual acuity of 20/270 with binocular viewing (20/360 OD and 20/270 OS) as measured with preferential looking, cycloplegic refraction of +9.50 S OD and +9.00 S OS, and esotropia of 30 prism diopters (Appendix 1). On the fundus exam, slightly increased pigmentation was noted in the parafoveal area. Scotopic ERG testing performed at BCH showed response amplitudes below the 99% prediction interval for normal. Photopic function was also considerably attenuated, with b-wave responses below the normal mean for his age by two standard deviations ([Figure 2A](#f2){ref-type="fig"}). The responses did not demonstrate an electronegative waveform. The amplitudes of the 30-Hz flicker response were 10% of normal. His dark-adapted visual threshold was found to be elevated by 1.46 log units. These findings resulted in an initial diagnosis of LCA.

![Exam findings for Patient 2. **A**: Electroretinograms (ERGs) recorded from Patient 2's right eye at 5 months old (black traces). Scotopic and photopic responses closest in flash strength to International Society for Clinical Electrophysiology of Vision (ISCEV) standards are shown. Mixed-response ERGs at 1.3 cd·s/m^2^ are shown instead of at the traditional 3.0 cd·s/m^2^ flash strength. Light-adapted ERGs at 2.25 cd·s/m^2^ are shown instead of at the traditional 3.0 cd·s/m^2^ flash strength. Scotopic ERG testing showed response amplitudes below the 99% prediction interval for normal, with prolonged b-wave implicit times \[[@r69]\]. Photopic function was also significantly attenuated, with b-wave responses below the normal mean for his age by two standard deviations and implicit times prolonged \[[@r70]\]. The amplitude of the 30-Hz flicker response was 10 µV, about 10% of normal. Control ERGs performed at the same institution for a healthy 10-month-old are included for comparison (red traces). DA = dark adapted; LA = light adapted. **B**: Right and left fundus photographs at age 3 years, showing red foveal areas and increased pigmentation in the parafoveal area. **C**: Family pedigree of Patient 2. Stripes indicate a maternal aunt with Stargardt disease.](mv-v23-695-f2){#f2}

Patient 2 was followed regularly at BCH, and his best-corrected visual acuity improved to 20/150 OD and 20/200 OS by age 3. His hyperopia increased slightly to +11.00 OU. He continued to have alternating esotropia of 30 prism diopters, and no stereopsis was demonstrated with the Lang test. At age 3, on a clinical exam, blunted foveal reflexes and a faint bull's eye pattern in the macula were noted but were not evident on fundus photography ([Figure 2B](#f2){ref-type="fig"}). At age 6, ERG testing showed improved scotopic responses compared to previous recordings, with b-wave amplitudes of approximately half the lower normal limit. Cone response amplitudes were 20% of normal. The amplitudes of the 30-Hz flicker were 20--25% of normal. At that visit, color vision testing was essentially normal, with only a few minor errors on the Ishihara plate test. Cycloplegic refraction was +11.50 sphere in both eyes. Best-corrected letter acuity was 20/100 OD and 20/70 −2 OS. Nystagmus and esotropia were present (Appendix 1).

At that time, further comprehensive genetic testing, which included sequencing all of the known inherited retinal disease (IRD) genes \[[@r25]\], showed a c.4487G\>A mutation in *CACNA1F*, leading to a p.(Gly1496Glu) change. This position was highly conserved ([Figure 3A](#f3){ref-type="fig"}), and this mutation was predicted to be deleterious (PolyPhen-2, SIFT, Protein Variation Effect Analyzer (PROVEAN), and [MutationTaster](http://www.mutationtaster.org/); [Table 1](#t1){ref-type="table"}) \[[@r29],[@r32]-[@r34]\]. Family history was significant for a maternal aunt with Stargardt disease ([Figure 2C](#f2){ref-type="fig"}). There was no history of consanguinity in the family.

![Schematics. **A**: Schematic showing the conservation of the amino acid p.(Gly1496Glu) across the genomes of ten species. **B**: Schematic of the CACNA1F transmembrane protein and the positions of mutations p.(Trp332\*) and p.(Gly1496Glu). (Adapted from \[[@r4]\]).](mv-v23-695-f3){#f3}

###### Prediction of pathogenicity of *CACNA1F* c.4487G\>A mutation leading to p.(Gly1496Glu) change.

   Variables                **Prediction software**   **Prediction**      **Score**
  ------------------------- ------------------------- ------------------- -----------
  Amino-Acid change         Polyphen-2                Probably Damaging   1
  SIFT                      Damaging                  0                   
  Provean                   Deleterious               −7.49               
  MutationTaster            Disease causing           0.9999              
  Nucleotide conservation   PhyloP                    Conserved           5.512
  PhastCons                 Conserved                 1                   
  GERP                      Conserved                 5.37                

Discussion
==========

The two patients described had early onset retinal degeneration and based on their clinical findings were initially diagnosed with LCA. Genetic diagnostic testing, however, did not identify mutations in known LCA genes. Instead, both patients were found to have mutations in the *CACNA1F* gene as the likely cause of their retinal disease, which is usually associated with CSNB2. These findings are important for several reasons. First, these findings demonstrate that phenotypes caused by mutations in different IRD genes overlap, and thus, it is difficult to predict genotype based on phenotypic characteristics. In particular, the phenotype of CSNB2 is intermediate between the archetypes of LCA (poor acuity, nystagmus, and hyperopia) and the more familiar form of CSNB1 (good acuity, less nystagmus in adulthood, and myopia). Further, clinical exams and electrophysiologic testing can be difficult in young children, compounding the clinical diagnostic challenge. The apparently atypical genetic diagnosis made for these patients emphasizes the importance of broad genetic diagnostic testing for patients with IRD, such as panel-based NGS tests \[[@r25],[@r35]-[@r37]\]. Finally, the findings reported highlight the importance of continued studies of the genetic causality of IRD, including investigation of potential modifier alleles that may contribute to determining the severity of disease \[[@r38]-[@r43]\].

The mutations in *CACNA1F* in the two patients reported here are novel, and we strongly believe these mutations are the disease-causing variants. The positions of both mutations are near other known pathogenic mutations in *CACNA1F* ([Figure 3B](#f3){ref-type="fig"}). The missense mutation \[p.(Gly1496Glu)\] in Patient 2 is predicted to be a deleterious change at a conserved position ([Table 1](#t1){ref-type="table"}), and Patient 1 has a nonsense mutation \[p.(Trp332\*)\] that causes a truncation at exon 7 (out of 48 in total) of *CACNA1F*, which is presumed to result in a null allele. Further, neither patient had potential disease-causing mutations in other known IRD genes.

Given the genetic diagnoses of *CACNA1F*-associated retinal degeneration, the clinical findings in the patients described demonstrate the overlap in symptoms and clinical findings between LCA and CSNB. The clinical presentations of both patients were consistent with LCA: decreased vision and nystagmus in infancy and significantly reduced photopic and scotopic ERG responses. Patient 2 also had high hyperopia and an abnormal fundus exam, usually associated with LCA, whereas patients with CSNB tend to have myopia. Although hyperopia in CSNB is less common, it has been reported in other studies \[[@r44]-[@r46]\]. Neither patient underwent an electronegative ERG when they presented. Patient 1 did not show this finding until months to years after the initial presentation, and Patient 2 did not develop an electronegative ERG, even at 6 years of age. A possible contributing factor is Patient 2's refractive error, as high hyperopia has been reported to correlate with increased b-wave amplitudes \[[@r47]\]. It has also been reported that the development of the characteristic electronegative waveform in CSNB can take time to manifest \[[@r48]\].

Both patients reported here were diagnosed with LCA but were found to have mutations in a "CSNB gene," demonstrating that different types of IRD cannot be separated based on phenotype alone. In addition, distinguishing between different types of IRD, such as LCA and CSNB, based on ERG findings can be problematic, especially in young children. ERGs are difficult to interpret in young infants as their amplitudes are smaller and increase with age \[[@r3],[@r49]\]. Thus, what may initially seem like severely reduced ERG amplitudes may improve on subsequent testing. This was observed in Patient 1, as his serial ERGs performed at one institution showed progressive development of retinal function over time. Furthermore, visual function during infancy can be initially profoundly subnormal and then improve months later, making early diagnosis challenging \[[@r48]\].

Adding to the already challenging task of differentiating LCA and CSNB is that some patients with LCA can exhibit improvements in visual function temporarily \[[@r50]\]. Several studies have reported that certain patients, such as those with mutations in *RPE65* (Gene ID 6121, OMIM [180069](https://www.ncbi.nlm.nih.gov/omim/?term=180069)), may show improved visual function over the first few years of life and deteriorate only as they reach their third to fifth decades \[[@r51],[@r52]\].

One question raised by the findings presented here is why the retinal phenotypes produced by different mutations in genes associated with different types of retinal degeneration overlap. It does not appear that the primary mutations in the disease gene account completely for severity, as Patient 1 had clinically milder disease than Patient 2 but had a null allele of *CACNA1F*. This observation is common for patients with IRD, and it has been suggested that variants in additional genes may modify the severity of the phenotype from the primary mutation in *CACNA1F*, as has been suggested for other types of IRD \[[@r53]-[@r57]\]. Both patients had variants in other IRD genes ([Table 2](#t2){ref-type="table"}) that were ruled out as pathogenic but may function as modifier alleles.

###### Additional IRD gene variants in *CACNA1F* patients.

  **Patient ID**   **Gene**         **Transcript**   **Zygosity**   **cDNA position**   **Protein change**   **Polyphen-2**      **SIFT**      **Provean**       **MutationTaster**   **dbSNP**         **ExAC Frequency**
  ---------------- ---------------- ---------------- -------------- ------------------- -------------------- ------------------- ------------- ----------------- -------------------- ----------------- --------------------
  1                *SEMA4A*         NM_022367.3      heterozygous   c.2138G\>A          p.(Arg713Gln)        Possibly damaging   Tolerated     Neutral           Polymorphism         rs41265017        A=4,297/ G=121,356
  *PDE6A*          NM_000440.2      heterozygous     c.251A\>T      p.(Lys84Met)        Benign               Damaging            Deleterious   Polymorphism      NA                   T=11/ A=121,396   
  *PDE6B*          NM_000283.3      heterozygous     c.1412C\>T     p.(Ala471Val)       Benign               Damaging            Neutral       Polymorphism      rs182071364          T=17/ C=119,914   
  *RPGR ^a^*       NM_001034853.1   hemizygous       c.1163C\>T     p.(Ala388Val)       Benign               Tolerated           Neutral       Polymorphism      rs199661899          T=16/ C=85,833    
  2                *USH2A*          NM_206933.2      heterozygous   c.9286G\>A          p.(Val3096Met)       Probably damaging   Damaging      Neutral           Polymorphism         rs147267500       A=6/ G=121,394
  *PDE6A*          NM_000440.2      heterozygous     c.1214A\>G     p.(Asn405Ser)       Probably damaging    Damaging            Deleterious   Disease causing   rs145107955          G=20/ A=121,278   

*^a^* Known polymorphism reported in \[[@r71]\].

The cases reported here exemplify the wide range of phenotypic variability encompassed by mutations in *CACNA1F*, which can present as CSNB2 or with LCA-like symptoms, or as AIED, CORDX3, or XLRP, as previously reported \[[@r18]-[@r20]\]. As indicated above, similar phenotypic variations are observed with many other forms of IRD. We believe these findings support broader use of genetic diagnostic testing for patients with IRD. This is especially true of making a correct diagnosis of the condition underlying nystagmus in the newborn. Multiple groups have reported successful application of panel-based tests and whole-exome sequencing to patients with IRD \[[@r25],[@r58]-[@r62]\]. The present data suggest that panel-based testing is more accurate than exome sequencing at present, and as the costs of whole-genome sequencing continue to fall, this modality may be applied more broadly for clinical diagnostic testing \[[@r25],[@r63]\]. In concert with increased use of genetic diagnostic testing, we encourage clinicians to adopt a genotype-based system of disease classification, as this approach is more precise and will facilitate identification of patients who may benefit from gene-based therapies for these disorders, which show great promise in ongoing clinical trials \[[@r64]-[@r68]\].
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